Every material Form 8-K BlossomHill Therapeutics, Inc. has filed with the SEC since August 10, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
BlossomHill Therapeutics reported a second-quarter 2026 net loss of $23.8 million, or $(8.75) per share, up from $13.2 million, or $(5.51) per share, a year earlier, as research and development and general and administrative expenses rose. The company said its August 2026 initial public offering brought in $168.3 million in gross proceeds, and that it expects its cash and IPO proceeds to fund operations into the second quarter of 2028.
Q2 2026 net loss was $23.8 million, or $(8.75) per share, versus $13.2 million, or $(5.51) per share, in Q2 2025.
R&D expenses rose to $21.4 million from $12.5 million; G&A expenses rose to $3.3 million from $1.6 million.
Cash and cash equivalents were $95.4 million at June 30, 2026; the August 2026 IPO sold 10,516,240 shares for $168.3 million gross.
The FDA granted Fast Track designation to BH-30643 for advanced EGFR C797S-positive NSCLC; an end-of-phase 1 meeting is planned for Q4 2026.
BlossomHill Therapeutics presented updated Phase 1/2 SOLARA trial data for its investigational EGFR inhibitor BH-30643 in lung cancer patients with the EGFR C797S resistance mutation, at the IASLC 2026 World Conference on Lung Cancer. The filing reports a 45% objective response rate in 40 patients, which the company says has no approved targeted therapy, and it plans a Phase 2 study starting in Q1 2027.
Objective response rate of 45% (18 of 40 patients, 95% CI 29%-62%); disease control rate of 88% (35 of 40) as of the May 12, 2026 data cutoff
Treatment-related dose reductions and discontinuations occurred in 9% and 3% of 174 patients treated at 40 mg, 50 mg and 60 mg twice daily
Median follow-up was 6.9 months; the company plans a global Phase 2 study in EGFR C797S-positive NSCLC in Q1 2027
Presentation follows FDA Fast Track designation for BH-30643 in advanced or metastatic EGFR C797S-positive NSCLC
BlossomHill Therapeutics, Inc. closed its initial public offering on August 10, 2026, selling 9,375,000 shares of common stock at $16.00 per share. The company also adopted an amended and restated certificate of incorporation and amended and restated bylaws in connection with the closing. The filing gives gross proceeds before underwriting discounts and offering expenses, which are not yet deducted.
IPO of 9,375,000 shares of common stock at $16.00 per share, closed August 10, 2026
Approximate aggregate gross proceeds of $150.0 million, before underwriting discounts, commissions and estimated offering expenses
Amended and restated certificate of incorporation filed with Delaware Secretary of State; restated bylaws adopted effective August 10, 2026
Restated bylaws were previously filed as Exhibit 3.4 to Form S-1 (File No. 333-297512) on July 17, 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every BlossomHill Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →